Puma Biotechnology Inc (PBYI)

40.60
NASDAQ : Health Care
Prev Close 39.95
Day Low/High 38.10 / 41.00
52 Wk Low/High 19.74 / 73.27
Avg Volume 991.40K
Exchange NASDAQ
Shares Outstanding 36.95M
Market Cap 1.48B
EPS -8.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Figure 1: Treatment-Emergent Diarrhea, CONTROL Vs ExteNET (Graphic: Business Wire)

Figure 1: Treatment-Emergent Diarrhea, CONTROL Vs ExteNET (Graphic: Business Wire)

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that interim results from a Phase II clinical trial of Puma's investigational drug PB272 (neratinib) were presented at the 2017 American...

A Waterfall Plot Showing

A Waterfall Plot Showing "% Change In Size Of Target Lesions" From Puma Biotechnology's FB-10 Trial In HER2-positive Metastatic Breast Cancer Is Attached. (Graphic: Business Wire)

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that interim results from the Phase Ib/II FB-10 clinical trial of Puma's investigational drug PB272 (neratinib) given in combination with the...

Puma Biotechnology Presents Results From The Phase II SUMMIT Trial Of PB272 For ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer At The 2017 AACR Annual Meeting

Puma Biotechnology Presents Results From The Phase II SUMMIT Trial Of PB272 For ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer At The 2017 AACR Annual Meeting

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 (neratinib) were presented at the 2017 American...

Puma Biotechnology Launches Expanded Access Program For PB272 (Neratinib) For U.S. Patients With HER2-Positive Breast Cancer Or HER2-Mutated Cancers

Puma Biotechnology Launches Expanded Access Program For PB272 (Neratinib) For U.S. Patients With HER2-Positive Breast Cancer Or HER2-Mutated Cancers

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, has initiated an expanded access program (EAP) in the United States to provide its investigational therapy, PB272 (neratinib), to patients with...

Finding Bullish and Bearish Market Reversals

Finding Bullish and Bearish Market Reversals

These stocks are showing signs of changing direction.

Biotechs Among 5 Stocks Setting Up for Major Breakouts

Biotechs Among 5 Stocks Setting Up for Major Breakouts

Here's how to rake in the profits off some potential big breakouts.

Biotech Stock Mailbag: Puma's Rebound Explained, TG Therapeutics Approval Debate, Aurinia Next Steps

Biotech Stock Mailbag: Puma's Rebound Explained, TG Therapeutics Approval Debate, Aurinia Next Steps

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

These Stocks Are Trending Up With Monster Volume

These Stocks Are Trending Up With Monster Volume

Let's take a look at several stocks that are experiencing unusual volume activity.

7 Stocks Trending Up With Monster Volume

7 Stocks Trending Up With Monster Volume

Here's a technical look at how to play a number of stocks trending higher with strong volume.

Puma Biotechnology To Present At Cowen's Health Care Conference

Puma Biotechnology To Present At Cowen's Health Care Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

Dow Declines, Caterpillar Weighs on Index as Feds Swarm Offices

Dow Declines, Caterpillar Weighs on Index as Feds Swarm Offices

Wall Street declines on Thursday as investors catch their breath following a massive, record-breaking rally a day earlier.

Stocks Slide as Rally Runs Out of Steam; Snap Makes Trading Debut

Stocks Slide as Rally Runs Out of Steam; Snap Makes Trading Debut

Stocks are mostly lower, retreating from records as Wall Street struggles to find the momentum to push stocks higher after Wednesday's massive rally.

Biotech Premarket Movers: Aurinia, Puma, PTC, Juno

Biotech Premarket Movers: Aurinia, Puma, PTC, Juno

Aurinia Pharmaceuticals, Puma Biotechnology, PTC Therapeutics and Juno Therapeutics were among the biotech stock movers in premarket trading on Thursday.

What You Need to Know About Roche AG's Breast Cancer Drug Perjeta

What You Need to Know About Roche AG's Breast Cancer Drug Perjeta

Roche said patients treated with Perjeta combined with Herceptin and chemotherapy after surgery saw lower death risks and tumor return rates.

Roche Shares Soar, Puma Bio Sinks on Perjeta Breast Cancer Study Win

Roche Shares Soar, Puma Bio Sinks on Perjeta Breast Cancer Study Win

Roche shares surged in Zurich Thursday after the Swiss drugmaker said trials of its key breast cancer drug showed solid results when compared to chemotherapy.

Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2017

Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2017

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced publication of abstracts on neratinib for the American Association for Cancer Research (AACR) Annual Meeting 2017.

Puma Biotechnology Provides Update On Review Of Marketing Authorisation Application For PB272

Puma Biotechnology Provides Update On Review Of Marketing Authorisation Application For PB272

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that based on its recent meeting with the Rapporteur, Co-Rapporteur and review team members, as well as the European Medicines Agency (EMA),...

Puma Biotechnology Reports Fourth Quarter And Full Year 2016 Financial Results

Puma Biotechnology Reports Fourth Quarter And Full Year 2016 Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2016.

Puma Biotechnology To Present At RBC Capital Markets Healthcare Conference

Puma Biotechnology To Present At RBC Capital Markets Healthcare Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology To Present At LEERINK Partners Global Healthcare Conference

Puma Biotechnology To Present At LEERINK Partners Global Healthcare Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?

Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Newman Ferrara LLP Announces Corporate Governance Investigation Of Puma Biotechnology, Inc. - PBYI

Newman Ferrara LLP Announces Corporate Governance Investigation Of Puma Biotechnology, Inc. - PBYI

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Puma Biotechnology, Inc.

Puma Biotechnology Expands Cohort In Phase II SUMMIT Trial Of PB272 In HER2 Mutation-Positive Cancer Patients

Puma Biotechnology Expands Cohort In Phase II SUMMIT Trial Of PB272 In HER2 Mutation-Positive Cancer Patients

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, has expanded the fourth cohort from its Phase II SUMMIT clinical trial of its lead drug candidate PB272 (neratinib) as a single agent in patients with...

Puma Biotechnology To Present At J.P. Morgan Healthcare Conference

Puma Biotechnology To Present At J.P. Morgan Healthcare Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

First Week of PBYI February 2017 Options Trading

First Week of PBYI February 2017 Options Trading

Investors in Puma Biotechnology, Inc. saw new options begin trading this week, for the February 2017 expiration.

Puma Biotechnology To Move Stock Exchange Listing To Nasdaq

Puma Biotechnology To Move Stock Exchange Listing To Nasdaq

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that it will voluntarily move its stock exchange listing from the New York Stock Exchange to the Nasdaq Stock Market.